Fluidigm (FLDM) Upgraded at BidaskClub

BidaskClub upgraded shares of Fluidigm (NASDAQ:FLDM) from a hold rating to a buy rating in a research report released on Wednesday.

Several other equities research analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Fluidigm from a hold rating to a sell rating in a research report on Monday, August 27th. ValuEngine upgraded shares of Fluidigm from a sell rating to a hold rating in a research report on Saturday, June 2nd.

Fluidigm stock opened at $8.10 on Wednesday. Fluidigm has a 12-month low of $4.43 and a 12-month high of $8.62. The stock has a market cap of $327.02 million, a P/E ratio of -6.81 and a beta of 3.44. The company has a quick ratio of 1.64, a current ratio of 2.05 and a debt-to-equity ratio of 4.79.

Fluidigm (NASDAQ:FLDM) last released its quarterly earnings data on Thursday, August 2nd. The medical research company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.03). Fluidigm had a negative return on equity of 104.75% and a negative net margin of 53.65%. The firm had revenue of $26.43 million for the quarter, compared to analyst estimates of $26.30 million. equities research analysts predict that Fluidigm will post -0.99 earnings per share for the current year.

In related news, insider Levin Capital Strategies, L.P. purchased 20,029 shares of the company’s stock in a transaction on Friday, July 27th. The stock was acquired at an average cost of $6.14 per share, for a total transaction of $122,978.06. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders have acquired 170,239 shares of company stock valued at $899,796. Company insiders own 2.20% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in FLDM. Wells Fargo & Company MN increased its position in shares of Fluidigm by 64.8% during the first quarter. Wells Fargo & Company MN now owns 28,945 shares of the medical research company’s stock valued at $169,000 after acquiring an additional 11,377 shares during the last quarter. Trexquant Investment LP acquired a new position in shares of Fluidigm in the first quarter valued at approximately $165,000. Engineers Gate Manager LP acquired a new position in shares of Fluidigm in the first quarter valued at approximately $128,000. BlackRock Inc. grew its holdings in shares of Fluidigm by 1.3% in the first quarter. BlackRock Inc. now owns 2,212,763 shares of the medical research company’s stock valued at $12,923,000 after purchasing an additional 27,881 shares in the last quarter. Finally, New York State Common Retirement Fund grew its holdings in shares of Fluidigm by 47.9% in the first quarter. New York State Common Retirement Fund now owns 38,900 shares of the medical research company’s stock valued at $227,000 after purchasing an additional 12,600 shares in the last quarter. Institutional investors and hedge funds own 96.73% of the company’s stock.

Fluidigm Company Profile

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.

Featured Story: What is a closed-end mutual fund (CEF)?

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply